52 -7 (93) 2026 - Bobojonov I.Sh. - SURUNKALI BUYRAK KASALLIGINING III VA V BOSQICHLARIDA TGF-Β1 GENI POLIMORFIZMI HAMDA BUYRAK ICHKI GEMODINAMIKASI KO‘RSATKICHLARI O‘RTASIDAGI BOG‘LIQLIK

SURUNKALI BUYRAK KASALLIGINING III VA V BOSQICHLARIDA TGF-Β1 GENI POLIMORFIZMI HAMDA BUYRAK ICHKI GEMODINAMIKASI KO‘RSATKICHLARI O‘RTASIDAGI BOG‘LIQLIK

Bobojonov I.Sh. - Toshkent Davlat Tibbiyot Universiteti

Rezyume

Ushbu maqolada surunkali buyrak kasalligining III va V bosqichlarida Transforming Growth Factor Beta 1 (TGF-β1) geni polimorfizmi hamda buyrak ichki gemodinamikasi ko‘rsatkichlari o‘rtasidagi o‘zaro bog‘liqlik tahlil qilingan. Surunkali buyrak kasalligi dunyo miqyosida keng tarqalgan bo‘lib, uning rivojlanishi va progressiv kechishida genetik omillar, xususan TGF-β1 geni muhim ahamiyat kasb etadi. Tadqiqotda TGF-β1 geni polimorfizmi molekulyar-genetik usullar yordamida aniqlanib, buyrak ichki gemodinamikasi Doppler ultratovush tekshiruvi orqali baholangan. Bemorlarda rezistentlik indeksi, pulsatsiya indeksi, maksimal sistolik va yakuniy diastolik qon oqimi tezligi kabi gemodinamik ko‘rsatkichlar genotiplarga nisbatan qiyosiy tahlil qilingan. Olingan natijalar TGF-β1 geni polimorfizmi buyrak mikrosirkulyatsiyasidagi o‘zgarishlar va kasallikning og‘irlashish darajasi bilan uzviy bog‘liqligini ko‘rsatadi. Mazkur tadqiqot natijalari surunkali buyrak kasalligini erta prognozlash, yuqori xavf guruhiga mansub bemorlarni aniqlash hamda shaxsga yo‘naltirilgan diagnostika va davolash strategiyalarini ishlab chiqishda muhim ilmiy-amaliy ahamiyatga ega.

Kalit so'zlar: Surunkali buyrak kasalligi, TGF-β1 geni, gen polimorfizmi, buyrak ichki gemodinamikasi, Doppler ultratovush, buyrak fibrozi, rezistentlik indeksi, genetik marker, nefrologiya, prognoz.

First page

357

Last page

364

For citation:Bobojonov I.Sh. - SURUNKALI BUYRAK KASALLIGINING III VA V BOSQICHLARIDA TGF-Β1 GENI POLIMORFIZMI HAMDA BUYRAK ICHKI GEMODINAMIKASI KO‘RSATKICHLARI O‘RTASIDAGI BOG‘LIQLIK//New Day in Medicine 7(93)2026 357-364 https://newdayworldmedicine.com/en/new_day_medicine/7-93-2026

List of References

1. Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. doi: 10.1016/j.kint.2023.10.016.
2. Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4 Suppl):S117-S314. doi: 10.1016/j.kint.2023.10.018.
3. Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80:309-326. doi: 10.1146/annurev-physiol-022516-034227.
4. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684-696. doi: 10.1038/nrneph.2011.149.
5. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: The master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325-338. doi: 10.1038/nrneph.2016.48.
6. Eddy AA, López-Guisa JM. Renal fibrosis: From pathogenesis to novel therapeutic approaches. Pediatr Nephrol. 2020;35(11):2131-2146.
7. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5.
8. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3.
9. O'Neill WC. Atlas of Renal Ultrasonography. Philadelphia (PA): Saunders Elsevier; 2014.
10. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, editors. Brenner and Rector's The Kidney. 11th ed. Philadelphia (PA): Elsevier; 2020.

    file

    download